Standard Article

Antiviral Market Overview

Development of Therapeutic Agents Handbook

  1. Anita Arora,
  2. Natalia Mendoza,
  3. Stephen K. Tyring

Published Online: 16 DEC 2011

DOI: 10.1002/9780470571224.pse425

Pharmaceutical Sciences Encyclopedia

Pharmaceutical Sciences Encyclopedia

How to Cite

Arora, A., Mendoza, N. and Tyring, S. K. 2011. Antiviral Market Overview. Pharmaceutical Sciences Encyclopedia. 8:1–17.

Author Information

  1. Center for Clinical Studies, Houston, Texas

Publication History

  1. Published Online: 16 DEC 2011


The past 15 years have seen significant progress in developing new antivirals. In 1990, there were just five drugs licensed as antiviral agents, whereas now there are approximately 40 drugs in the antiviral market repertoire, most being for the treatment of the human immunodeficiency virus (HIV). Over the years, one of the main attributes sought in a new antiviral is the capacity to treat patients who have developed resistance to existing treatments, and numerous compounds are investigated in such advanced-stage patients. The main need for antiviral agents, past, present, and likely in the future continues to be in the world's poorest countries. This chapter will provide a thorough overview of the antiviral market.


  • human immunodeficiency virus (HIV);
  • acquired immune deficiency syndrome (AIDS);
  • varicella-zoster virus;
  • cytomegalovirus;
  • influenza virus;
  • respiratory syncytial virus (RSV);
  • hepatitis B virus (HBV);
  • hepatitis C virus (HCV);
  • herpes simplex virus (HSV)